Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
166.22B
Market cap166.22B
Price-Earnings ratio
10.79
Price-Earnings ratio10.79
Dividend yield
3.27%
Dividend yield3.27%
Average volume
29.72M
Average volume29.72M
High today
$37.97
High today$37.97
Low today
$37.41
Low today$37.41
Open price
$37.55
Open price$37.55
Volume
4.99M
Volume4.99M
52 Week high
$91.90
52 Week high$91.90
52 Week low
$37.31
52 Week low$37.31

NVO News

Nasdaq 4h
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?

Key Points Hims stock has been under pressure this year. The company turned in solid Q4 results, but issued soft Q1 guidance. The stock has fallen to an attr...

Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
The Motley Fool 5h
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising. Hims & Hers (HIMS 1.39%) is in the middle of a ver...

Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
Nasdaq 18h
Why Shares of Novo Nordisk Stock Sank (Again) This Week

Key Points Novo Nordisk lost another head-to-head trial against Eli Lilly. The company is cutting prices on weight-loss drugs in 2026. The stock looks cheap,...

Why Shares of Novo Nordisk Stock Sank (Again) This Week

Analyst ratings

53%

of 34 ratings
Buy
38.2%
Hold
52.9%
Sell
8.8%

More NVO News

Simply Wall St 1d
Is Novo Nordisk Now Attractive After The Recent Share Price Slump?

If you are wondering whether Novo Nordisk’s recent share price slump has created a potential opportunity or a value trap, you are in the right place. The stock...

Is Novo Nordisk Now Attractive After The Recent Share Price Slump?
Nasdaq 2d
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies

Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weig...

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
Benzinga 2d
Novo Nordisk’s Crash Has Created A Rare Valuation Gap - Novo Nordisk - Benzinga

...

Novo Nordisk’s Crash Has Created A Rare Valuation Gap - Novo Nordisk - Benzinga
Benzinga 2d
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment

But beneath the selloff, something unusual has emerged. Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-g...

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment
Benzinga 2d
Ozempic Price War - Novo Nordisk Slashes Prices By 50%

Novo Nordisk A/S (NYSE:NVO) shares are down during Wednesday’s premarket session. The down move comes as the company announced plans to cut the list prices of i...

Ozempic Price War - Novo Nordisk Slashes Prices By 50%
Nasdaq 2d
Novo Nordisk Partners Vivtex To Develop Next-generation Oral Medicines For Obesity And Diabetes

(RTTNews) - Danish drugmaker Novo Nordisk and biotechnology company Vivtex Corp. announced Wednesday a partnership to develop next-generation oral biologic medi...

Novo Nordisk Partners Vivtex To Develop Next-generation Oral Medicines For Obesity And Diabetes
TipRanks 2d
Novo Nordisk, Vivtex announce partnership to develop oral obesity/diabetes drugs

The company states: “Novo Nordisk (NVO) and Vivtex Corporation announced a partnership to develop next-generation oral biologic medicines for obesity, diabetes...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.